Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Stempoint Capital Lp
Form 13F · Q2 2026

Stempoint Capital Lp

CIK 1952142Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$581M
Reported book value
85
Positions
11
Quarters on record
Top 50
Positions

Stempoint Capital Lp — holdings

Top 50 positions of 85, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1TNGX Tango Therapeutics Inc1.2M+508.7%$38M6.6%
2ABIVAX SA Abivax Sa283,657−9.6%$38M6.5%
3RVMD Revolution Medicines Inc159,943−43.2%$30M5.2%
4ERAS Erasca Inc1.6M+552.8%$29M4.9%
5TYRA Tyra Biosciences Inc632,754+227.6%$20M3.5%
6DNTH Dianthus Therapeutics Inc200,851+134.9%$20M3.4%
7ELVN Enliven Therapeutics Inc346,914−4.5%$18M3.0%
8MLYS Mineralys Therapeutics Inc602,686+13.0%$16M2.8%
9BHVN Biohaven Ltd1.1M−33.3%$16M2.7%
10SRZN Surrozen Inc602,798+14.7%$14M2.4%
11KINIKSA PHARMACEUTICALS INTL Kiniksa Pharmaceuticals Intl209,234—$13M2.3%
12SRRK Scholar Rock Hldg Corp239,146−76.9%$13M2.3%
13ALKS Alkermes Plc248,015+208.1%$13M2.2%
14TRAX First Tracks Biotherapeutics622,723—$13M2.2%
15PRAX Praxis Precision Medicines I37,243−33.8%$12M2.1%
16ROIV Roivant Sciences Ltd348,408−9.7%$12M2.1%
17BIOA Bioage Labs Inc464,171+37.1%$11M2.0%
18CGON Cg Oncology Inc159,349−22.5%$11M2.0%
19ORKA Oruka Therapeutics Inc116,461—$11M1.9%
20IMVT Immunovant Inc276,527−63.0%$11M1.8%
21CELC Celcuity Inc98,203+63.5%$10M1.8%
22RLMD Relmada Therapeutics Inc1.5M+144.4%$10M1.7%
23CLYM Climb Bio Inc742,745—$10M1.7%
24SYRE Spyre Therapeutics Inc106,926−36.2%$9M1.6%
25ZURA Zura Bio Ltd1.4M+81.6%$8M1.4%
26INFLARX NV Inflarx Nv3.2M—$7M1.2%
27AMLX Amylyx Pharmaceuticals Inc384,304−42.6%$7M1.2%
28CLDX Celldex Therapeutics Inc New178,412−29.8%$7M1.1%
29OVID Ovid Therapeutics Inc2.4M—$7M1.1%
30EQ Equillium Inc2.0M—$6M1.1%
31DFTX Definium Therapeutics Inc137,124−57.9%$6M1.1%
32CYTK Cytokinetics Inc75,603−41.7%$6M1.1%
33DMRA Damora Therapeutics Inc216,194—$6M1.0%
34IVA Inventiva Sa1.4M—$5M0.9%
35IPSC Century Therapeutics Inc2.1M—$5M0.9%
36AURA Aura Biosciences Inc714,280—$5M0.9%
37EYPT Eyepoint Inc338,471−58.3%$5M0.8%
38ASMB Assembly Biosciences Inc170,378−8.1%$5M0.8%
39WHWK Whitehawk Therapeutics Inc1.0M+8.7%$5M0.8%
40XENE Xenon Pharmaceuticals Inc76,075−46.0%$5M0.8%
41UNIQURE NV Uniqure Nv88,115+12.9%$4M0.7%
42CMPS Compass Pathways Plc284,769—$4M0.7%
43AVALYN PHARMACEUTICALS INC Avalyn Pharmaceuticals Inc118,000—$4M0.7%
44MPLT Maplight Therapeutics Inc106,906+6.9%$4M0.7%
45ALMS Alumis Inc135,736−40.9%$4M0.7%
46AXSM Axsome Therapeutics Inc.15,375—$4M0.6%
47GLUE Monte Rosa Therapeutics Inc153,544—$4M0.6%
48ACAD Acadia Pharmaceuticals Inc143,167−41.0%$4M0.6%
49SLDB Solid Biosciences Inc358,780+83.6%$4M0.6%
50PSNL Personalis Inc247,783—$3M0.6%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.